Date filters select awards with transaction activity in the period. Amounts below are lifetime award obligations. IDV values remain separate.
CAMZYOS 5 MGDepartment of Veterans Affairs$6.2K obligationsEnds Mar 10, 2026
POMALYST 2MG, 4MGDepartment of Veterans Affairs$127.2K obligationsEnds Mar 6, 2026
BREYANZI 50-110M CAR POS T-CELL CTNDepartment of Veterans Affairs$310.9K obligationsEnds Jan 12, 2025
REVLIMID AND POMALYST SPECIALTY PHARMACEUTICALS (FHCC)Department of Veterans Affairs$0 obligationsEnds Feb 19, 2026
POMALYST 2 MGDepartment of Veterans Affairs$11.2K obligationsEnds Feb 20, 2026
POMALYST 2MG, 4MGDepartment of Veterans Affairs$33.2K obligationsEnds Feb 20, 2026
POMALIDOMIDE(POMALYST)3MG CAPDepartment of Veterans Affairs$10.9K obligationsEnds Feb 20, 2026
CAMZYOS 5 MGDepartment of Veterans Affairs$6.2K obligationsEnds Feb 20, 2026
REVLIMID 10MG, 15MG, 25MGDepartment of Veterans Affairs$50.1K obligationsEnds Feb 13, 2026
THALIDOMIDE 100MGDepartment of Veterans Affairs$5.8K obligationsEnds Feb 13, 2026
POMALIDOMIDE(POMALYST) 4MG CAPDepartment of Veterans Affairs$16.4K obligationsEnds Feb 6, 2026
REVLIMID DIFFERENT DOSESDepartment of Veterans Affairs$65.5K obligationsEnds Feb 1, 2027
REVLIMID 10MG CAPDepartment of Veterans Affairs$22.6K obligationsEnds Mar 31, 2026
CAMZYOS, POMALYST, AND REVLIMIDDepartment of Veterans Affairs$110.0K obligationsEnds Jul 20, 2026
MAVACAMTEN IS AN OUTPATIENT DRUG USED IN THE TREATMENT OF SPECIFIC TYPES OF CARDIOMYOPATHIES.Department of Veterans Affairs$327.5K obligationsEnds Sep 30, 2026
REVLIMID, POMALYST, CAMZYOS SPECIALTY PHARMACEUTICALSDepartment of Veterans Affairs$848.4K obligationsEnds Oct 31, 2026
BREYANZI CAR T CELL THERAPYDepartment of Veterans Affairs$335.0K obligationsEnds Apr 30, 2026
ABECMA TRANSPLANT DRUGDepartment of Veterans Affairs$338.9K obligationsEnds Mar 4, 2026
BREYANZI FOR CAR TDepartment of Veterans Affairs$335.0K obligationsEnds Feb 15, 2026
BREYANZI CAR T THERAPY FOR TVHS TRANSPLANT CENTERDepartment of Veterans Affairs$335.0K obligationsEnds Feb 6, 2026
ABECMA INJ, SUSP, TRANSPLANT TREATMENT, NATIONAL DRUG CODE 59572-0515-0.Department of Veterans Affairs$0 obligationsEnds Oct 20, 2025
ABECMA INJECTION FOR TRANSPLANT PATIENTDepartment of Veterans Affairs$0 obligationsEnds Apr 19, 2025
LENALIDOMIDEDepartment of Veterans Affairs$9.8K obligationsEnds Nov 7, 2025
ABECMA FOR CAR-TDepartment of Veterans Affairs$338.9K obligationsEnds Jan 8, 2026
ABECMA FOR TRANSPLANT PATIENTDepartment of Veterans Affairs$0 obligationsEnds Jun 5, 2025